OM DENNE EPISODE
Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes.
He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of 'clinical anarchy' if data is not recorded and optimised.
Dr Gerstung describes international data sharing as a necessary step for personalised therapy.
He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of 'clinical anarchy' if data is not recorded and optimised.
Dr Gerstung describes international data sharing as a necessary step for personalised therapy.
Engelsk
USA
UDSKRIFT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SØG BLANDT TIDLIGERE EPISODER
Søg efter gamle afsnit af IBCD 2016.
ANDRE EPISODE I DENNE PODCAST
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays.
He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay developm…
Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment.
She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match patie…
Dr Beer speaks with ecancertv at IBCD 2016 about making use of genomic data in a clinically actionable setting.
He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries.
Dr Beer describes how unregulated access and of…
Dr Golfinopoulos meets with ecancertv at IBCD 2016 to discuss SPECTA: a screening platform that sought to encourage patients to participate in clinical trials.
He describes how regulatory involvement in trial design and drug design could be streamlined, and the issue of reimbursement for personali…
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra ecancer.org, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
REDIG
Tak fordi du hjælper med at holde podcast-databasen opdateret.
